Epkinly: Breaking Down The Promising Data
- Epkinly (generic name epcoritamab-bysp) is a bispecific T-cell engager. In late 2025, Eplinky, given alongside rituximab + lenalidomide, became the first bispecific antibody combination ever approved for follicular lymphoma as a second-line treatment option.
- The trial that led to the combination’s approval suggests that adding Epkinly significantly improves how long a patient can go without their lymphoma progressing — and does so with a manageable safety profile.
- Lymphoma experts say Epkinly plus standard treatment with rituximab + lenalidomide will likely become the standard second-line treatment for follicular lymphoma patients.
- For patients and families, that could mean longer remissions, fewer toxic chemotherapies, and better quality of life outside the hospital.
For patients and families, Epkinly (epcoritamab-bysp) offers a new source of hope, a powerful treatment that works differently from traditional chemotherapy, and that may offer better control with more flexibility.
Read MoreEpkinly: A New Approach to Fighting Lymphoma
Epkinly (generic name epcoritamab-bysp) is a bispecific T-cell engager. It’s a drug designed to bring two types of cells together: a patient’s own immune T-cells on one side, and the lymphoma B-cells on the other, and prompt the T-cells to kill the cancer cells. Unlike many other treatments, Epkinly is given subcutaneously (a shot under the skin), which makes it more convenient than traditional IV infusions at a hospital.Before 2025, Epkinly was already approved for people whose lymphoma had returned or not responded after two or more prior therapies, including certain types of DLBCL and FL.
What’s new, and why the oncology world is paying close attention, is that in November 2025, the U.S. FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or refractory follicular lymphoma even earlier in the treatment course. Epkinly with rituximab + lenalidomide, also known as Epkinly R², is now the first bispecific antibody combination ever approved for FL as a second-line treatment option.
Epkinly R² Shows Promise In Trial
The approval is based on results from the phase 3 “EPCORE FL-1” trial, which enrolled 488 adults with relapsed or refractory follicular lymphoma. Participants were randomized to receive either:
- Epkinly + rituximab + lenalidomide
- Rituximab + lenalidomide alone
The risk of disease progression or death was reduced by 79% in the Epkinly arm compared with the control group.
At the time of interim analysis (i.e, before the study is completed), median progression-free survival (the period of time when the patients remain with stable disease) was not reached in the Epkinly group, meaning more than half of patients were still progression-free at the time of analysis vs 11.2 months in the control arm.
These results suggest that adding Epkinly significantly improves how long a patient can go without their lymphoma progressing — and does so with a manageable safety profile. That’s why many lymphoma experts say Epkinly + standard treatment will likely become the main second-line option for FL.
Who Should Consider Epkinly?
Even with strong data, using Epkinly involves thoughtful decision-making. Some of the factors doctors and patients look at when discussing it include:
- How aggressive or repetitive the patient’s lymphoma is: Because the Epkinly-based regimen showed the biggest benefit in people who already had relapsed or refractory disease, it’s especially appealing when the disease has returned quickly or repeatedly.
- Convenience and lifestyle: Because Epkinly is subcutaneous (not a long IV infusion), it can be more convenient for people concerned about time, travel, and hospital stays.
- Prior treatments and goals of care: If a patient has already had multiple therapies, or is sensitive to chemotherapy toxicity, Epkinly offers a potentially effective, chemo-sparing alternative that may preserve quality of life for longer.
In short, Epkinly doesn’t replace all prior options, but for many patients, it offers a powerful new choice that balances effectiveness with practicality.
What Patients Should Do Now
Epkinly’s recent FDA approval marks a milestone: it brings a potent, T-cell engaging immunotherapy into a position earlier in the treatment journey for follicular lymphoma. For patients and families, that could mean longer remissions, fewer toxic chemotherapies, and more of life outside the hospital.
That said, Epkinly is part of a broader, evolving landscape. Additional trials are ongoing to test it in other lymphomas, earlier disease settings, and in combination with different therapies.
If you or a loved one has relapsed follicular lymphoma, it’s a good time to talk with your oncologist about whether Epkinly might be a fit, especially now that it’s FDA-approved in combination with rituximab + lenalidomide.
Questions To Ask Your Doctor
- Should I consider this newly FDA-approved drug, Epkinly?
- What are the risks vs. benefits of Epkinly?
- How often would I need to come in for treatment and/or monitoring?
- Can I, or should I, add it to my current treatment plan?
Learn more about SurvivorNet's rigorous medical review process.
